Table 1.
Summary of treatment-related adverse events associated with select checkpoint inhibitor therapies.
| Treatment-Related Adverse Events | PD-1 Inhibitor | PD-L1 Inhibitor | CTLA-4 Inhibitor | |
|---|---|---|---|---|
| Nivolumab | Pembrolizumab | Atezolizumab | Ipilimumab | |
| Any adverse event | 30–85% | 40–75% | 16–67% | 55–96% |
| Skin | ||||
| Pruritus | 2–22% | 4–21% | 5–14% | 25–36% |
| Rash | 4–24% | 8–21% | 5–15% | 15–34% |
| Vitiligo | 3–11% | 9–25% | NR | 2–9% |
| Gastrointestinal | ||||
| Diarrhea | 7–22% | 7–20% | 5–20% | 23–46% |
| Colitis | 1–9% | 1–4% | 1–2% | 7–25% |
| Hepatic | ||||
| ALT Increase | 1–8% | 2–8% | 2–4% | 0–15% |
| AST increase | 1–12% | 3–10% | 2–4% | 1–13% |
| Hepatitis | 0–5% | 1–2% | 1–2% | 0–9% |
| Endocrine | ||||
| Hypothyroidism | 4–10% | 7–14% | 2–7% | 1–15% |
| Hyperthyroidism | 0–5% | 3–10% | 1% | 0–2% |
| Hypophysitis | <1% | 1–2% | <1% | 2–16% |
| Respiratory | ||||
| Pneumonitis | 1–9% | 2–6% | 1–4% | 0.4–4% |
| Source Publications | [20,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49] | [48,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65] | [66,67,68,69,70,71,72,73,74,75] | [20,46,47,48,49,65,76,77,78,79,80,81,82] |
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NR: No Reported Data.